NR4A1 and breast cancer: In another study, postmenopausal women with hormone receptor–positive (HR+) early-stage BC treated with aromatase inhibitors (AIs) were randomly assigned to one of two groups: one receiving only AIs and the other one receiving educational materials plus AIs.